Table 2.

List of tested neoantigen peptide

Mutated peptideWild-type peptide
PatientGeneAA substitutionPeptide lengthSequenceAffinity (IC50, nmol/L)SequenceAffinity (IC50, nmol/L)HLA-AMedian RPKM
12066FGD2F164Y9IYQFHSQYF10IYQFHSQFF8HLA-A24:02178.2
XKP349H10IYMYVCAHLL13IYMYVCAPLL18HLA-A24:02141.6
BRAFL711F9LFPQIFASI43LFPQILASI156HLA-A24:02232.7
12183BRAPR534C9QLCDVMFYL5QLRDVMFYL25HLA-A02:01596.6
ARFGEF2D809Y10YLPEEYLSSI10DLPEEYLSSI2338HLA-A02:011314
12231BSCL2T423M9LLMEANLPA5LLTEANLPA31HLA-A02:012335.3
EHMT1A275V10YMATTKSQTV28YMATTKSQTA287HLA-A02:011375.3
12475TYMSA231T10TLLTYMIAHI20ALLTYMIAHI16HLA-A02:01852.3
12705MAP1SS569F10STFHSGFPPV34STSHSGFPPV224HLA-A02:012349.7
12832GINS1I87V9YLYDRLLRV3YLYDRLLRI5HLA-A02:01461.4
RFC5K160N9YLSNIIPAL4YLSKIIPAL4HLA-A02:01565.6
BAP1E20K9TLLVKDFGV23TLLVEDFGV21HLA-A02:011914.2
12912ATP13A3R54P10LLYWMPEWPV5LLYWMPEWRV8HLA-A02:012375.7
GFOD2G11V10KMLPGVGVFV9KMLPGVGVFG1465HLA-A02:01402.1
  • NOTE: RPKM data were obtained from RNA sequencing data of TCGA (28) ovarian serous cystadenocarcinoma.